Effects of soy isoflavone extract supplements on blood pressure in adult humans: Systematic review and meta-analysis of randomized placebo-controlled trials

Journal of Hypertension

Volumn 28, Issue 10, 2010, Pages 1971-1982

  Taku, Kyoko ^a   Lin, Ning ^a,b   Cai, Donglian ^b   Hu, Jianwei ^c   Zhao, Xiaohui ^c   Zhang, Yumei ^c   Wang, Peiyu ^d   Melby, Melissa K ^a   Hooper, Lee ^e   Kurzer, Mindy S ^f   Mizuno, Shoichi ^g   Ishimi, Yoshiko ^a   Watanabe, Shaw ^a  

^a NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Department of Nutrition and Food Hygiene ^*  (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^f UNIVERSITY OF MINNESOTA   (United States)

^g Center for Collaboration and Partnership   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGLYMAX; ASCORBIC ACID; DAIDZEIN; DAIDZEIN PLUS GENISTEIN; DAIDZEIN PLUS GENISTEIN PLUS GLYCITEIN; DIENOGEST PLUS ESTRADIOL VALERATE; ESSENTIAL NUTRITION; ESTROMINERAL; GENISTEIN; GLYCITEIN; ISOFLAVONE DERIVATIVE; MAXISOY; NOVASOY; PHYTOLIFE; RALOXIFENE; SOYLIFE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; SOYBEAN; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 77957253371     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833c6edb     Document Type: Article

References (50)

1. The epidemiology of hypertension. In: Committee on the Guidelines for the Management of Hypertension from the Japanese Society of Hypertension, editor. Guidelines for the management of hypertension (JSH2009) [in Japanese]. Tokyo: Life Science Publishing; 2009. pp. 1 -7.
2. Lawes CM, RodgersA, Bennett DA, Parag V, Suh I, UeshimaH, MacMahon S. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003; 21:707-716.
3. Lida M, Ueda K, Okayama A, Kodama K, Sawai K, ShibataS, et al.Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese - Nippon data 80. J Hum Hypertens 2003; 17:851-857.
4. Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, Shinohara N, et al. Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke 2000; 31:2616-2622.
5. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
7. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2008; 88:38-50.
8. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.0.2 [upadated September 2009]. The Cochrane Collaboration; 2008. http://www.cochrane-handbook.org. [Accessed 11 November 2009]
9. Balk E, Chung M, Chew P, Ip S, Raman G, KupelnickB, et al.Effects of soy on health outcomes: evidence report/technology assessment no.126 [AHRQ publication no. 05-E024-2]. Rockville, Maryland, USA: Agency for Healthcare Research and Quality; 2005.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12.
11. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
12. Ballantyne JC, Carr DB, deFerranti S, Suarez T, Lau J, Chalmers TC, et al. The comparative effects of postoperative analgesic therapies on pulmonary outcome: cumulative meta-analyses of randomized, controlled trials. Anesth Analg 1998; 86:598-612.
13. Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 2007; 85:1148-1156.
14. Colacurci N, Chiantera A, Fornaro F, de Novellis V, Manzella D, Arciello A, et al. Effects of soy isoflavones on endothelial function in healthy postmenopausal women. Menopause 2005; 12:299-307.
15. Garrido A, De la Maza MP, Hirsch S, Valladares L. Soy isoflavones affect platelet thromboxane A2 receptor density but not plasma lipids in menopausal women. Maturitas 2006; 54:270-276.
16. Gleason CE, Carlsson CM, Barnet JH, Meade SA, Setchell KD, Atwood CS, et al.A preliminary study of the safety, feasibility and cognitive efficacy of soy isoflavone supplements in older men and women. Age Ageing 2009; 38:86-93.
17. Gonzalez S, Jayagopal V, Kilpatrick ES, Chapman T, Atkin SL. Effects of isoflavone dietary supplementation on cardiovascular risk factors in type 2 diabetes. Diabetes Care 2007; 30:1871-1873.
18. Han KK, Soares JM Jr, Haidar MA, de Lima GR, Baracat EC. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 2002; 99:389-394.
19. Hutchins AM, McIver IE, Johnston CS. Soy isoflavone and ascorbic acid supplementation alone or in combination minimally affect plasma lipid peroxides in healthy postmenopausal women. J Am Diet Assoc 2005; 105:1134-1137.
20. Katz DL, Evans MA, Njike VY, Hoxley ML, Nawaz H, Comerford BP, Sarrel PM. Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women. Climacteric 2007; 10:500-507.
21. Khaodhiar L, Ricciotti HA, Li L, Pan W, Schickel M, Zhou J, Blackburn GL. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause 2008; 15:125-132.
22. Simons LA, von Konigsmark M, Simons J, Celermajer DS. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol 2000; 85:1297-1301.
23. Squadrito F, Altavilla D, Morabito N, Crisafulli A, D'Anna R, Corrado F, et al.The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Atherosclerosis 2002; 163: 339-347.
24. Uesugi S, Watanabe S, Ishiwata N, Uehara M, Ouchi K. Effects of isoflavone supplements on bone metabolic markers and climacteric symptoms in Japanese women. Biofactors 2004; 22:221-228.
25. Yao S, Wang Y, Que Y. Effects of Phytoestrogen on serum NO level and cerebral blood flow in postmenopausal women [in Chinese]. Mod Pract Med 2007; 19:820-821.
26. Yildiz MF, Kumru S, Godekmerdan A, Kutlu S. Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women. Int J Gynaecol Obstet 2005; 90:1 28-133.
27. Zhang L, Pu K. Study of soy isoflavones on improving the large arterial elasticity in patients with metabolic syndrome [in Chinese]. J Clin Res 2006; 23:578-579.
28. Kenny AM, Mangano KM, Abourizk RH, Bruno RS, Anamani DE, Kleppinger A, et al. Soy proteins and isoflavones affect bone mineral density in older women: a randomized controlled trial. Am J Clin Nutr 2009; 90:1-9.
29. He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 2002; 16:761-770.
30. Neter JE, Stam BE, KokFJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42:878-884.
31. Arai Y, Watanabe S, Kimira M, Shimoi K, Mochizuki R, Kinae N. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr 2000; 130:2243-2250.
32. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006; 8:538-554.
33. KuiperGG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al.Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139:4252-4263.
34. Walker HA, Dean TS, Sanders TA, Jackson G, Ritter JM, Chowienczyk PJ. The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17beta-estradiol. Circulation 2001; 103:258-262.
35. Li SH, Liu XX, Bai YY, Wang XJ, Sun K, Chen JZ, et al. Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women: a meta-analysis of randomized placebo-controlled trials. Am J Clin Nutr 2010; 91:480-486.
36. Grassi D, Desideri G, Croce G, Tiberti S, Aggio A, Ferri C. Flavonoids, vascular function and cardiovascular protection. Curr Pharm Des 2009; 15:1072-1084.
37. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999; 103:401-406.
38. Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G. Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 2003; 88:2135-2140.
39. Higashi Y, Yoshizumi M. Exercise and endothelial function: role of endothelium-derived nitric oxide and oxidative stress in healthy subjects and hypertensive patients. Pharmacol Ther 2004; 102:87-96.
40. Amin HM, Ahmad S, Walenga JM, Hoppensteadt DA, Leitz H, Fareed J. Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders. Clin Appl Thromb Hemost 2000; 6:71-76.
41. Gottstein N, Ewins BA, Eccleston C, Hubbard GP, Kavanagh IC, Minihane AM, et al. Effect of genistein and daidzein on platelet aggregation and monocyte and endothelial function. Br J Nutr 2003; 89:607-616.
42. Peluso MR, Winters TA, Shanahan MF, Banz WJ. A cooperative interaction between soy protein and its isoflavone-enriched fraction lowers hepatic lipids in male obese Zucker rats and reduces blood platelet sensitivity in male Sprague-Dawley rats. J Nutr 2000; 130:2333-2342.
43. Hall WL, Rimbach G, Williams CM. Isoflavones and endothelial function. Nutr Res Rev 2005; 18:130-144.
44. Morito K, Hirose T, Kinjo J, Hirakawa T, Okawa M, Nohara T, et al. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull 2001; 24:351-356.
45. Morito K, Aomori T, Hirose T, Kinjo J, Hasegawa J, Ogawa S, et al. Interaction of phytoestrogens with estrogen receptors alpha and beta (II). Biol Pharm Bull 2002; 25:48-52.
46. Setchell KD, Brown NM, Zimmer-Nechemias L, Brashear WT, Wolfe BE, Kirschner AS, Heubi JE. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr 2002; 76:447-453.
47. Setchell KD. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 1998; 68:1333S-1346S.
48. Arai Y, Uehara M, Sato Y, Kimira M, Eboshida A, Adlercreutz H, Watanabe S. Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol 2000; 10:127-135.
49. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol: a clue to the effectiveness of soy and its isoflavones. J Nutr 2002; 132:3577-3584.
50. Wu J, Oka J, Tabata I, Higuchi M, TodaT, Fuku N, et al.Effects of isoflavone and exercise on BMD and fat mass in postmenopausal Japanese women: a 1-year randomized placebo-controlled trial. J Bone Miner Res 2006; 21:780-789.